{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:35:10Z","timestamp":1761896110643},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T00:00:00Z","timestamp":1442275200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13063-015-0925-5","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T03:47:01Z","timestamp":1442288821000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Harmonizing Optimal Strategy for Treatment of coronary artery diseases \u2013 comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"16","author":[{"given":"Joo Myung","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hyun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Seok","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Kyu","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jang-Whan","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay Young","family":"Rhew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Bin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Kyu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Mo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Jae","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bon-Kwon","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Kyeong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Yong","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hyo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Woon","family":"Rha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Dae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Ho","family":"Chae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Soo","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,15]]},"reference":[{"key":"925_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e356","volume":"344","author":"M Schmidt","year":"2012","unstructured":"Schmidt M, Jacobsen JB, Lash TL, Botker HE, Sorensen HT. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ. 2012;344, e356.","journal-title":"BMJ"},{"key":"925_CR2","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1161\/01.cir.0000441139.02102.80","volume":"129","author":"AS Go","year":"2014","unstructured":"Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics\u20132014 update: a report from the American Heart Association. Circulation. 2014;129:e28\u2013292.","journal-title":"Circulation"},{"key":"925_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1527-3466.2007.00027.x","volume":"25","author":"JA Jakubowski","year":"2007","unstructured":"Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007;25:357\u201374.","journal-title":"Cardiovasc Drug Rev"},{"issue":"35","key":"925_CR4","first-page":"2541","volume":"2014","author":"S Windecker","year":"2014","unstructured":"Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. ESC\/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;2014(35):2541\u2013619.","journal-title":"Eur Heart J"},{"key":"925_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00228-009-0737-1","volume":"66","author":"DS Small","year":"2010","unstructured":"Small DS, Kothare P, Yuen E, Lachno DR, Li YG, Winters KJ, et al. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol. 2010;66:127\u201335.","journal-title":"Eur J Clin Pharmacol"},{"key":"925_CR6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ahj.2008.08.031","volume":"157","author":"KH Mak","year":"2009","unstructured":"Mak KH, Bhatt DL, Shao M, Hankey GJ, Easton JD, Fox KA, et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J. 2009;157:658\u201365.","journal-title":"Am Heart J"},{"key":"925_CR7","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","volume":"367","author":"MT Roe","year":"2012","unstructured":"Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297\u2013309.","journal-title":"N Engl J Med"},{"key":"925_CR8","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","volume":"374","author":"R Mehran","year":"2009","unstructured":"Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149\u201359.","journal-title":"Lancet"},{"key":"925_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.109.878017","volume":"121","author":"SJ Pocock","year":"2010","unstructured":"Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation. 2010;121:43\u201351.","journal-title":"Circulation"},{"key":"925_CR10","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/S0140-6736(12)61223-9","volume":"380","author":"M Sabate","year":"2012","unstructured":"Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet. 2012;380:1482\u201390.","journal-title":"Lancet"},{"key":"925_CR11","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.jacc.2011.07.031","volume":"58","author":"KW Park","year":"2011","unstructured":"Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. J Am Coll Cardiol. 2011;58:1844\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"925_CR12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jcin.2013.12.201","volume":"7","author":"KW Park","year":"2014","unstructured":"Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, et al. Everolimus-eluting xience v\/promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. J Am Coll Cardiol Intv. 2014;7:471\u201381.","journal-title":"J Am Coll Cardiol Intv"},{"key":"925_CR13","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jacc.2012.11.015","volume":"61","author":"KW Park","year":"2013","unstructured":"Park KW, Lee JM, Kang SH, Ahn HS, Yang HM, Lee HY, et al. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries. J Am Coll Cardiol. 2013;61:536\u201344.","journal-title":"J Am Coll Cardiol"},{"key":"925_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/eurheartj\/eht570","volume":"35","author":"SH Kang","year":"2014","unstructured":"Kang SH, Park KW, Kang DY, Lim WH, Park KT, Han JK, et al. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J. 2014;35:1147\u201358.","journal-title":"Eur Heart J"},{"key":"925_CR15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jacc.2013.05.022","volume":"62","author":"T Palmerini","year":"2013","unstructured":"Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabate M, Valgimigli M, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2013;62:496\u2013504.","journal-title":"J Am Coll Cardiol"},{"key":"925_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jcin.2013.04.011","volume":"6","author":"PW Serruys","year":"2013","unstructured":"Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. J Am Coll Cardiol Intv. 2013;6:777\u201389.","journal-title":"J Am Coll Cardiol Intv"},{"key":"925_CR17","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.4244\/EIJV7I12A224","volume":"7","author":"L Raber","year":"2012","unstructured":"Raber L, Kelbaek H, Ostoijc M, Baumbach A, Tuller D, von Birgelen C, et al. Comparison of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial infarction (COMFORTABLE AMI trial): rationale and design. EuroIntervention. 2012;7:1435\u201343.","journal-title":"EuroIntervention"},{"key":"925_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jacc.2013.09.061","volume":"63","author":"T Palmerini","year":"2014","unstructured":"Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabate M, Smits PC, et al. Clinical outcomes with bioabsorbable polymer\u2013versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2014;63:299\u2013307.","journal-title":"J Am Coll Cardiol"},{"key":"925_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)61852-2","volume":"381","author":"PC Smits","year":"2013","unstructured":"Smits PC, Hofma S, Togni M, Vazquez N, Valdes M, Voudris V, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet. 2013;381:651\u201360.","journal-title":"Lancet"},{"key":"925_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jacc.2013.04.045","volume":"62","author":"M Natsuaki","year":"2013","unstructured":"Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2013;62:181\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"925_CR21","unstructured":"Windecker S. BIORESORBABLE POLYMER-BASED DES ARE THE RIGHT CHOICE TO MINIMIZE STENT THROMBOSIS! TCT. 2014."},{"key":"925_CR22","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736\u201347.","journal-title":"Circulation"},{"issue":"82","key":"925_CR23","first-page":"E1","volume":"2013","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD, Casey Jr DE, Chung MK, de Lemos JA, et al. ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013;2013(82):E1\u201327.","journal-title":"Catheter Cardiovasc Interv"},{"key":"925_CR24","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/j.jacc.2011.01.036","volume":"57","author":"GG Stefanini","year":"2011","unstructured":"Stefanini GG, Serruys PW, Silber S, Khattab AA, van Geuns RJ, Richardt G, et al. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J Am Coll Cardiol. 2011;57:2221\u201332.","journal-title":"J Am Coll Cardiol"},{"key":"925_CR25","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344\u201351.","journal-title":"Circulation"},{"key":"925_CR26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.4244\/EIJV5I7A146","volume":"5","author":"P Vranckx","year":"2010","unstructured":"Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. EuroIntervention. 2010;5:871\u20134.","journal-title":"EuroIntervention"},{"key":"925_CR27","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","volume":"57","author":"G Campo","year":"2011","unstructured":"Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol. 2011;57:2474\u201383.","journal-title":"J Am Coll Cardiol"},{"key":"925_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1745-6215-13-29","volume":"13","author":"KW Park","year":"2012","unstructured":"Park KW, Park BE, Kang SH, Park JJ, Lee SP, Cha KS, et al. The \u2018Harmonizing Optimal Strategy for Treatment of coronary artery stenosis\u2013sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen\u2019 (HOST-ASSURE) trial: study protocol for a randomized controlled trial. Trials. 2012;13:29.","journal-title":"Trials"},{"key":"925_CR29","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315.","journal-title":"N Engl J Med"},{"key":"925_CR30","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1093\/eurheartj\/ehr126","volume":"32","author":"SP Boer de","year":"2011","unstructured":"de Boer SP, Lenzen MJ, Oemrawsingh RM, Simsek C, Duckers HJ, van der Giessen WJ, et al. Evaluating the \u2018all-comers\u2019 design: a comparison of participants in two \u2018all-comers\u2019 PCI trials with non-participants. Eur Heart J. 2011;32:2161\u20137.","journal-title":"Eur Heart J"},{"key":"925_CR31","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155\u201366.","journal-title":"N Engl J Med"},{"key":"925_CR32","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1001\/jama.2012.10065","volume":"308","author":"L Raber","year":"2012","unstructured":"Raber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tuller D, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA. 2012;308:777\u201387.","journal-title":"JAMA"},{"key":"925_CR33","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/eurheartj\/ehs086","volume":"33","author":"GG Stefanini","year":"2012","unstructured":"Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33:1214\u201322.","journal-title":"Eur Heart J"},{"key":"925_CR34","doi-asserted-by":"publisher","first-page":"835","DOI":"10.4244\/EIJV7I7A131","volume":"7","author":"SK Yazdani","year":"2011","unstructured":"Yazdani SK, Vorpahl M, Nakano M, Su SH, Kolodgie FD, Virmani R. In vitro and in vivo characterisation of biodegradable polymer-based drug-eluting stent. EuroIntervention. 2011;7:835\u201343.","journal-title":"EuroIntervention"},{"key":"925_CR35","first-page":"2591","volume":"6","author":"S Mura","year":"2011","unstructured":"Mura S, Hillaireau H, Nicolas J, Le Droumaguet B, Gueutin C, Zanna S, et al. Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int J Nanomedicine. 2011;6:2591\u2013605.","journal-title":"Int J Nanomedicine"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-015-0925-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-015-0925-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-015-0925-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T20:35:19Z","timestamp":1475786119000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-015-0925-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,15]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1186\/s13063-015-0925-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,15]]},"article-number":"409"}}